keyword
MENU ▼
Read by QxMD icon Read
search

I-131 Therapy

keyword
https://www.readbyqxmd.com/read/28811561/analysis-of-risk-factors-of-rapid-thyroidal-radioiodine-131-turnover-in-graves-disease-patients
#1
Ruiguo Zhang, Jian Tan, Renfei Wang, Guizhi Zhang, Qiang Jia, Zhaowei Meng, Yueqian Zhang
Rapid iodine-131((131)I) turnover in the thyroid gland is an important feature of Graves' disease (GD) and also a strong predictor of radioiodine therapy failure. The aim of this study was to explore the predictors of rapid (131)I turnover. The clinical data on 2543 patients were retrospectively reviewed. Patients were divided into 2 groups depending on present or absent with rapid (131)I turnover defined as a 4-hour to 24-hour (131)I uptake ratio of ≥1. Overall, 590 cases (23.2%) had a rapid (131)I turnover...
August 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28798811/pregnancy-testing-in-patients-undergoing-radiation-therapy
#2
Shivam M Kharod, Julie Greenwalt, Camille Dessaigne, Anamaria Yeung
Radiation therapy (RT) can be lethal to a developing fetus; therefore, determining pregnancy status before RT is essential. We here sought to determine how many women treated with RT at our institution for over one year were at risk for pregnancy when starting RT. We retrospectively reviewed the medical records of all female patients 12-55 years old treated with radiation, i.e. 1 October 2012 to 31 September 2013. Patients were categorised as 'at risk' if they had a uterus and 'no risk' if they had a hysterectomy...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28792635/favorable-results-in-abo-incompatible-renal-transplantation-without-b-cell-targeted-therapy-advantages-and-disadvantages-of-rituximab-pretreatment
#3
Manabu Okada, Yoshihiko Watarai, Kenta Iwasaki, Kenta Murotani, Kenta Futamura, Takayuki Yamamoto, Takahisa Hiramitsu, Makoto Tsujita, Norihiko Goto, Shunji Narumi, Asami Takeda, Kunio Morozumi, Kazuharu Uchida, Takaaki Kobayashi
The effectiveness of desensitization with rituximab in ABO-incompatible renal transplantation (ABO-I) has been widely reported. However, ABO-I outcomes are still worse than those of ABO-identical or ABO-compatible renal transplantation (ABO-Id/C). We retrospectively examined the outcomes in consecutive living donor ABO-Id/C (n = 412) and ABO-I (n = 205) cases to elucidate the causes of inferiority in ABO-I. ABO-I cases included recipients treated with rituximab (RIT, n = 131), splenectomy (SPX, n = 21), or neither because of low anti-A/B antibody titers (NoR/S, n = 53)...
August 9, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28776731/correlations-of-ctla-4-exon-1-49-a-g-and-promoter-region-318%C3%A2-c-t-polymorphisms-with-the-therapeutic-efficacy-of-131-i-radionuclide-in-graves-disease-in-chinese-han-population
#4
Xin-Rui Han, Xin Wen, Shan Wang, Shao-Hua Fan, Juan Zhuang, Yong-Jian Wang, Zi-Feng Zhang, Meng-Qiu Li, Bin Hu, Qun Shan, Chun-Hui Sun, Ya-Xing Bao, Sha Luan, Chang-Jiu Zhao, Dong-Mei Wu, Jun Lu, Yuan-Lin Zheng
This study aimed to investigate the correlation of CTLA-4 exon-1 49 A/G and promoter region-318 C/T polymorphisms with the therapeutic efficacy of radionuclide (131) I for Graves' disease in Chinese Han population. The (131) I radionuclide therapy was applied in 261 patients with Graves' disease. The patients were classified into the remission and non-remission groups. PCR-RFLP was implemented to detect CTLA-4 exon-1 49 A/G and promoter region-318 C/T polymorphisms. Haplotypes of CTLA-4 49 A/G and -318 C/T were analyzed using SHEsis software online...
August 4, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28751451/131i-labeled-anti-her2-camelid-sdab-as-a-theranostic-tool-in-cancer-treatment
#5
Matthias D'Huyvetter, Jens De Vos, Catarina Xavier, Marek Pruszynski, Yann G J Sterckx, Sam Massa, Geert Raes, Vicky Caveliers, Michael Zalutsky, Tony Lahoutte, Nick Devoogdt
<p>Camelid single-domain antibody-fragments (sdAbs) have beneficial pharmacokinetic properties, and those targeted to HER2 can be used for imaging of HER2-overexpressing cancer. Labeled with a therapeutic radionuclide, they may be used for HER2-targeted therapy. Here we describe the generation of a (131)I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.</p> <br />Experimental Design: <p>Anti-HER2 sdAb 2Rs15d was labeled with (131)I using [(131)I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2(+) murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab...
July 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28736501/design-of-radioiodinated-pharmaceuticals-structural-features-affecting-metabolic-stability-towards-in-vivo-deiodination
#6
REVIEW
Lorenzo Cavina, Dion van der Born, Peter H M Klaren, Martin C Feiters, Otto C Boerman, Floris P J T Rutjes
Radioiodinated pharmaceuticals are convenient tracers for clinical and research investigations because of the relatively long half-lives of radioactive iodine isotopes (i.e., (123)I, (124)I, and (131)I) and the ease of their chemical insertion. Their application in radionuclide imaging and therapy may, however, be hampered by poor in vivo stability of the C-I bond. After an overview of the use of iodine in biology and nuclear medicine, we present here a survey of the catabolic pathways for iodinated xenobiotics, including their biodistribution, accumulation, and biostability...
June 30, 2017: European Journal of Organic Chemistry
https://www.readbyqxmd.com/read/28719405/clinical-outcomes-1-year-after-empiric-131i-therapy-for-hyperthyroid-disorders-real-life-experience-and-predictive-factors-of-functional-response
#7
Lavinia Vija Racaru, Charlotte Fontan, Mathilde Bauriaud-Mallet, Séverine Brillouet, Olivier Caselles, Slimane Zerdoud, Delphine Bastié, Delphine Vallot, Philippe Caron, Manuel Bardiès, Frederic Courbon
: Radioiodine is a therapeutic option in Europe for Graves' disease (GD) and toxic multinodular goiter (MNG). PURPOSE: To compare empiric and calculated I activities using 2013 EANM recommendations. To look for predictive factors of therapeutic response to an empiric activity of I. To assess clinical situations favoring calculated treatment modalities. PATIENTS AND METHODS: Prospective monocentric study of clinical outcomes at 1 year follow-up in 86 patients with GD and MNG who received empiric I therapeutic activities (348-939 MBq)...
July 17, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28715040/-taste-dysfunction-dysgeusia-and-radioiodine-therapy-of-thyroid-cancer-be-aware-of-side-effects-by-antidepressants-and-sedatives
#8
Markus Dietlein, Alexander Drzezga
In addition to xerostomia, taste dysfunction (hypo-, dysgeusia) is an independent side effect of radioiodine therapy of thyroid cancer. Hypogeusia results from damage of the small mucous salivary glands in the vicinity of the taste buds. Particularly in those patients, who are treated with drugs such as antidepressants or sedatives, taste dysfunction becomes frequently clinically symptomatic. If feasible, therapy regimens bearing a potential risk for taste dysfunction should be switched. Additional damage to taste function should be minimalized, including cessation of smoking, change of agents for dental hygiene, and change of toothpaste...
July 17, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28710805/a-method-to-measure-the-absorbed-dose-of-the-thyroid-during-i-131-therapy-using-a-collar-detector-system-and-a-spect-acquisition
#9
Koen van Gils, Peter Brinks, Jules Lavalaye, Hein J Verberne, Jan B A Habraken
PURPOSE: Due to variations in biological half-life, accurate thyroid dosimetry for I-131 therapy is not trivial in clinical practice. In recent publications, systems are described to measure the uptake of I-131 in the thyroid repeatedly over time. In this work we present a method to calculate patient specific pharmacokinetics and absorbed dose using such a collar detector system (CoTI) in combination with a SPECT acquisition and a two-compartment model fit. METHODS: For three patients receiving I-131 therapy for benign thyroid conditions, the complete uptake profile is measured over a period of 15 to 25 days after administration...
July 15, 2017: Medical Physics
https://www.readbyqxmd.com/read/28699814/survival-times-for-cats-with-hyperthyroidism-treated-with-a-3-35-mci-iodine-131-dose-a-retrospective-study-of-96-cases
#10
Marie Vagney, Loic Desquilbet, Edouard Reyes-Gomez, Françoise Delisle, Patrick Devauchelle, Maria Isabel Rodriguez-Piñeiro, Dan Rosenberg, Pauline de Fornel-Thibaud
Objectives Radioiodine ((131)I) dose determination using radiotracer kinetic studies or scoring systems, and fixed relatively high (131)I dose (ie, 4 or 5 mCi) administration, are effective and associated with prolonged survival times for hyperthyroid cats. The latter method is less complicated but could expose patients and veterinary personnel to unnecessary levels of radiation. The aim of this study was to retrospectively evaluate the efficacy of a fixed 3.35 mCi (131)I dose for the treatment of 96 hyperthyroid cats with no length estimation for any palpated goitre ⩾20 mm, assess outcome and identify factors associated with survival...
July 1, 2017: Journal of Feline Medicine and Surgery
https://www.readbyqxmd.com/read/28697940/characterization-of-perioperative-contralateral-stroke-after-carotid-endarterectomy
#11
W Darrin Clouse, Emel A Ergul, Virendra I Patel, R Todd Lancaster, Glenn M LaMuraglia, Richard P Cambria, Mark F Conrad
OBJECTIVE: Contralateral stroke is an infrequent cause of perioperative stroke after carotid endarterectomy (CEA). Whereas the risks of ipsilateral stroke complicating CEA have been discriminated, factors that lead to contralateral stroke are poorly defined. The purpose of this study was to identify the risk of perioperative (30-day) contralateral stroke after CEA as well as predisposing preoperative and operative factors. Its specific effect on long-term survival was interrogated. METHODS: The Vascular Study Group of New England (VSGNE) was queried from April 1, 2003, to February 29, 2016, for all CEAs...
July 8, 2017: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/28696016/central-nervous-system-relapse-of-rhabdomyosarcoma
#12
Brian De, Michael D Kinnaman, Leonard H Wexler, Kim Kramer, Suzanne L Wolden
PURPOSE: The optimal management of central nervous system (CNS) relapse of rhabdomyosarcoma (RMS) is unclear. We examined diagnosis, management, and outcomes of patients with RMS developing CNS relapse. METHODS: Records of 23 patients diagnosed with CNS relapse between 1999 and 2016 were reviewed. Median age at presentation of CNS relapse was 15 years (range, 1-34 years). High-risk features at initial presentation were as follows: 16 alveolar patients, 13 Stage IV, and 13 with primary tumor in parameningeal locations...
July 11, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28688088/early-stimulated-thyroglobulin-for-response-prediction-after-recombinant-human-thyrotropin-aided-radioiodine-therapy
#13
Hee Jeong Park, Jung-Joon Min, Hee-Seung Bom, Jahae Kim, Ho-Chun Song, Seong Young Kwon
OBJECTIVE: Measurement of recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin (Tg) is generally recommended 72 h after the second rhTSH injection. However, due to the acute effect of I-131 on thyrocytes, Tg measured after radioiodine therapy (RIT) would not accurately reflect the thyroid tissue burden. We aimed to determine predictive values of serum Tg level measured just before rhTSH-aided RIT and to compare the results obtained just after RIT in patients with differentiated thyroid carcinoma (DTC)...
July 7, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28682793/impact-of-pet-and-mri-threshold-based-tumor-volume-segmentation-on-patient-specific-targeted-radionuclide-therapy-dosimetry-using-clr1404
#14
Abigail E Besemer, Benjamin Titz, Joseph J Grudzinski, Jamey P Weichert, John S Kuo, H Ian Robins, Lance T Hall, Bryan P Bednarz
Variations in tumor volume segmentation methods in targeted radionuclide therapy (TRT) may lead to dosimetric uncertainties. This work investigates the impact of PET and MRI threshold-based tumor segmentation on TRT dosimetry in patients with primary and metastatic brain tumors. In this study, PET/CT images of five brain cancer patients were acquired at 6, 24, and 48 h post-injection of (124)I-CLR1404. The tumor volume was segmented using two standardized uptake value (SUV) threshold levels, two tumor-to-background ratio (TBR) threshold levels, and a T1 Gadolinium-enhanced MRI threshold...
July 6, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28680197/association-between-volumetric-analysis-of-lung-metastases-on-f-18-fluoro-2-deoxy-d-glucose-positron-emission-tomography-computed-tomography-and-short-term-progression-after-i-131-therapy-for-differentiated-thyroid-carcinoma
#15
Yasuhiro Maruoka, Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Koichiro Abe, Masayuki Sasaki, Hiroshi Honda
PURPOSE: Lung metastases (LMs) and their radioiodine uptake affect prognosis in patients with differentiated thyroid carcinoma (DTC). We herein investigate the value of metabolic tumor volume (MTV) in LMs on positron emission tomography/computed tomography (PET/CT) using 2-[F-18]-fluoro-2-deoxy-D-glucose (F-18 FDG PET/CT) in predicting short-term progression after initial I-131 therapy in DTC patients. MATERIALS AND METHODS: We retrospectively evaluated 111 DTC patients with LMs...
July 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28677070/i-131-biokinetics-of-remnant-normal-thyroid-tissue-and-residual-thyroid-cancer-in-patients-with-differentiated-thyroid-cancer-comparison-between-recombinant-human-tsh-administration-and-thyroid-hormone-withdrawal
#16
Chae Moon Hong, Choon-Young Kim, Seung Hyun Son, Ji-Hoon Jung, Chang-Hee Lee, Ju Hye Jeong, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn
OBJECTIVE: The aim of this study was to assess I-131 biokinetics in thyroid cancer and remnant tissue in patients with differentiated thyroid cancer using whole-body scan (WBS) and SPECT images acquired after I-131 therapy. The influence of thyroid stimulating hormone (TSH) stimulation method on the kinetics was also evaluated. METHODS: A total of 57 patients who received I-131 therapy (2.96-7.4 GBq) were retrospectively included. TSH stimulation was achieved by recombinant human thyrotropin (rhTSH) or by thyroid hormone withdrawal (THW)...
July 4, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28675163/long-term-efficacy-and-safety-of-cyclosporine-in-a-cohort-of-steroid-refractory-acute-severe-ulcerative-colitis-patients-from-the-eneida-registry-1989-2013-a-nationwide-multicenter-study
#17
I Ordás, E Domènech, M Mañosa, V García-Sánchez, E Iglesias-Flores, M Peñalva, A Cañas-Ventura, O Merino, F Fernández-Bañares, F Gomollón, M Vera, A Gutiérrez, E Garcia-Planella, M Chaparro, M Aguas, E Gento, F Muñoz, M Aguirresarobe, C Muñoz, L Fernández, X Calvet, C E Jiménez, M A Montoro, A Mir, M L De Castro, M F García-Sepulcre, F Bermejo, J Panés, M Esteve
OBJECTIVES: To determine the efficacy and safety of cyclosporine (CyA) in a large national registry-based population of patients with steroid-refractory (SR) acute severe ulcerative colitis (ASUC) and to establish predictors of efficacy and adverse events. METHODS: Multicenter study of SR-ASUC treated with CyA, based on data from the ENEIDA registry. SR-ASUC patients treated with infliximab (IFX) or sequential rescue therapy (CyA-IFX or IFX-CyA) were used as comparators...
July 4, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28666778/psma-ligands-in-prostate-cancer-probe-optimization-and-theranostic-applications
#18
REVIEW
Susanne Lütje, Roger Slavik, Wolfgang Fendler, Ken Herrmann, Matthias Eiber
Due to its selective overexpression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. So far, various PSMA ligands have been developed for radiolabeling with radioisotopes such as (68)Ga or (18)F which can be used for specific visualization and diagnosis of PSMA-expressing PCa. In addition, PSMA ligands suitable for radiolabeling with (131)I or (177)Lu have become available to the clinics, allowing PSMA-based radioligand therapies...
June 28, 2017: Methods: a Companion to Methods in Enzymology
https://www.readbyqxmd.com/read/28662775/improved-survival-with-definitive-chemoradiation-compared-to-definitive-radiation-alone-in-squamous-cell-carcinoma-of-the-vulva-a-review-of-the-national-cancer-database
#19
Yuan James Rao, Re-I Chin, Caressa Hui, David G Mutch, Matthew A Powell, Julie K Schwarz, Perry W Grigsby, Stephanie Markovina
BACKGROUND: It is unclear whether definitive chemoradiation (CRT) results in improved overall survival compared to radiation therapy (RT) alone in patients with vulvar cancer who are not candidates for surgery. We compared these treatment strategies in the National Cancer Database (NCDB). METHODS: We identified 1352 patients with pathologically-confirmed squamous cell carcinoma of the vulva treated with definitive RT (n=353) or definitive CRT (n=999) between 2003 and 2014 in the NCDB...
June 27, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28660918/iodine-131-labeled-transferrin-capped-polypyrrole-nanoparticles-for-tumor-targeted-synergistic-photothermal-radioisotope-therapy
#20
Xuejiao Song, Chao Liang, Liangzhu Feng, Kai Yang, Zhuang Liu
Combining different therapeutic functions within single tumor-targeted nanoscale delivery systems is promising to overcome the limitations of conventional cancer therapies. Herein, transferrin that recognizes transferrin receptors up-regulated on tumor cells is pre-labeled with iodine-131 ((131)I) and then utilized as the stabilizer in the fabrication of polypyrrole (PPy) nanoparticles. The obtained transferrin-capped PPy@Tf-(131)I nanoparticles could be used for tumor-targeted radioisotope therapy (RIT) and photothermal therapy (PTT), by employing beta-emission from (131)I and the intrinsic high near-infrared (NIR) absorbance of PPy, respectively...
June 29, 2017: Biomaterials Science
keyword
keyword
97180
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"